Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 613 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Function Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

NCT00622869
View directory record Official record
Conditions
Liver Transplantation
Interventions
Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT04953897
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study of Adults With Autism Spectrum Disorders

NCT01093768
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin, Vasopressin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

NCT01970176
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)

NCT06062017
View directory record Official record
Conditions
Blood Pressure, Hydration, Vascular Disease Risk
Interventions
Water and Potassium supplementation
Dietary Supplement
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 21, 2026, 8:01 AM EDT
Completed No phase listed Observational

Effect of Hormone Therapy on Renal Function

NCT04482920
View directory record Official record
Conditions
Transgenderism, Kidney Diseases, Kidney Injury
Interventions
p-aminohippurate clearance study, Iohexol infusion
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
17 Years to 30 Years
Enrollment
22 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 21, 2026, 8:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

NCT04678505
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3402
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

NCT00596518
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
PF-00734200
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Not applicable Interventional Results available

Exercise Trial in Chronic Kidney Disease

NCT01462097
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Aerobic exercise training, Health Education
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 21, 2026, 8:01 AM EDT
Completed No phase listed Observational

Comparison of Dialysis Therapies on Cognitive Function

NCT00597103
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Not applicable Interventional

Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Study

NCT02155127
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
walking
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Not applicable Interventional

A Study of Herbal Supplements in Cancer Survivors With Constipation

NCT07091084
View directory record Official record
Conditions
Constipation, Cancer, Functional Constipation
Interventions
MZRW
Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dietary Oxalate and Immune Cell Function

NCT03877276
View directory record Official record
Conditions
Kidney Stone
Interventions
Breakfast, Spinach smoothie, Kale smoothie, Blended smoothie, V spinach smoothie, Sodium oxalate drink
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652
View directory record Official record
Conditions
Heart Failure and Impaired Kidney Function
Interventions
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
3,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
166
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

NCT01215747
View directory record Official record
Conditions
Amyloidosis
Interventions
KIACTA (eprodisate disodium), Placebo
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Glendale, California • Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 4 Interventional

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

NCT00425126
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Epoetin Alfa
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional

LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function

NCT00003706
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pemetrexed disodium
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

NCT01372826
View directory record Official record
Conditions
Renal Impairment
Interventions
NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3, NKTR118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Phase 3 Interventional

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

NCT06217302
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

NCT00543075
View directory record Official record
Conditions
Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function
Interventions
Genasense (oblimersen, G3139)
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Weeks and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 21, 2026, 8:01 AM EDT
Not yet recruiting Not applicable Interventional

AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function

NCT05432765
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Phenotypic Personalized Medicine Dosing, Standard of Care Dosing
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

NCT05711381
View directory record Official record
Conditions
Renal Impairment
Interventions
HM15912
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tustin, California • Miami, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress

NCT05092854
View directory record Official record
Conditions
Fluid Retention, Sodium Retention, Heat Stress, Dehydration (Physiology), Renal Injury, Electrolyte and Fluid Balance Conditions
Interventions
PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital - Rapid Recovery, Placebo Supplement
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

NCT01320722
View directory record Official record
Conditions
Renal Function, Endothelial Function, Blood Pressure, Overweight, Obesity
Interventions
Vitamin D ergocalciferol, Probenecid, Allopurinol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 21, 2026, 8:01 AM EDT